Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients of either sex, aged 45 to 80 years old inclusively.~2. Patients with a history of one stroke sustained 3 to 6 months prior to study entry and confirmed by neuroimaging.~3. Patients with cognitive impairment (MoCA score \< 26).~4. Patients with moderate performance in activities of daily living (Barthel score = 61-80).~5. Agreement to use a reliable method of birth control for the duration of the study (men and women of reproductive potential).~6. Availability of signed patient information sheet (Informed Consent form) for participation in the clinical trial.~Exclusion Criteria:~1. Patients with a history of subarachnoid/parenchymatous/ventricular hemorrhage, brain neoplasm, or any other condition which has caused neurological dysfunction.~2. History of central nervous system (CNS) disorders, including:~   * inflammatory diseases of the CNS (G00-G09)~  * systemic atrophies primarily affecting the CNS (G10-G13)~  * extrapyramidal and movement disorders (G20-G26)~  * other degenerative diseases of the nervous system (G30-G32)~  * demyelinating diseases of the CNS (G35-G37)~  * epilepsy (G40-41)~  * polyneuropathies and other disorders of the peripheral nervous system (G60-64), with marked movement and/or sensory impairments that cause movement disorders~  * diseases of neuromuscular junction and muscle (G70-73)~  * hydrocephalus (G91)~  * compression of brain (G93.5).~3. Dementia (20 or less on the MMSE score).~4. Speech disorders affecting investigator-patient communication.~5. Prior diagnosis of heart failure defined by the New York Heart Association classification (1964) as IV Functional Classification or poorly treated hypothyroidism or diabetes mellitus.~6. Patients having unstable angina or myocardial infarction in the past 6 months.~7. History/suspicion of oncology of any location (except for benign neoplasms).~8. Any other co-morbidity which, in the opinion of the investigator, may affect patient participation in the clinical trial.~9. Patients allergic to/intolerant of any components of the study treatment.~10. Patients with hereditary lactose intolerance.~11. Malabsorption syndrome, including congenital or acquired lactase deficiency (or any other disaccharidase deficiency) and galactosemia.~12. Pregnancy, breast-feeding or unwillingness to use birth control during the study.~13. Patients who, from the investigator's point of view, will not comply with the observation requirements of the study or adhere to study drug dosing regimens.~14. Patients with a history of non-adherence to medication; mental disorder (except for cognitive deficits); or alcoholism or abuse of psychoactive substances, which, in the investigator's opinion, will compromise compliance with study procedures.~15. Patients who have used medications listed in 'Prohibited Concomitant Treatment' in the past week.~16. Participation in other clinical trials in the previous 3 months.~17. Patients who are related to any of the on-site research personnel directly involved in the conduct of the trial or are an immediate relative of the study investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).~18. Patients who work for MATERIA MEDICA HOLDING (i.e. the company's employees, temporary contract workers, appointed officials responsible for carrying out the research or immediate relatives of the aforementioned).

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- MMH-MAP (Type: EXPERIMENTAL): Tablet for oral use. Dose per administration: 2 tablets. 2 tablets twice daily (4 tablets/day). The tablets should be held in mouth without chewing until complete dissolution. The duration of treatment will be 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for 24 weeks, according to the MMH-MAP dosing regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).